A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive Interactions

SPECIAL REPORT

Breast Cancer

Results of TRODELVY^® real-world data

Skin Cancer

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome

Eur J Cancer

Jurlander RS, Guldbrandt LM, Holmstroem RB, Madsen K, Donia M, Haslund CA, Schmidt H, Bastholt L, Ruhlmann CH, Svane IM, Ellebaek E

doi: 10.1016/j.ejca.2024.115053

Lung, Respiratory and Thoracic Cancer

Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort

Lung Cancer

Swalduz A, Beau-Faller M, Planchard D, Mazieres J, Bayle-Bleuez S, Debieuvre D, Fallet V, Geier M, Cortot A, Couraud S, Daniel C, Domblides C, Pichon E, Fabre E, Larivé S, Lerolle U, Tomasini P, Wislez M, Missy P, Morin F, Westeel V, Auliac JB

doi: 10.1016/j.lungcan.2024.108038

EHA 2024

Leukemia

Real-world study showed that initiating the next treatment was significantly more common among patients treated with first-line acalabrutinib versus first-line ibrutinib

ASH 2024

Lymphoma

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

ASH 2024

Leukemia

Quizartinib shows improved rates of composite complete remission and reduced need for re-induction in real-world patients with FLT3-ITD-mutated AML

EHA 2024

Lymphoma

STARGLO: Glofitamab combination therapy shows significant benefits in patients with relapsed/refractory diffuse large B-cell lymphoma

Lung, Respiratory and Thoracic Cancer

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

JTO Clin Res Rep

Schmid S, Holer L, Gysel K, Koster KL, Rothschild SI, Boos LA, Frehner L, Cardoso Almeida S, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur WD, Allemann A, Waibel C, Von der Mühll-Schill C, Früh M, Mauti LA

doi: 10.1016/j.jtocrr.2024.100735

Leukemia

Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS

Int J Cancer

Song Z, Wang Y, Zhang D, Wang T, Liu N, Gao L, Wang L, Yang J

doi: 10.1002/ijc.35235

Related content

Results of TRODELVY® real-world data

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome

Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort

Real-world study showed that initiating the next treatment was significantly more common among patients treated with first-line acalabrutinib versus first-line ibrutinib

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Quizartinib shows improved rates of composite complete remission and reduced need for re-induction in real-world patients with FLT3-ITD-mutated AML

STARGLO: Glofitamab combination therapy shows significant benefits in patients with relapsed/refractory diffuse large B-cell lymphoma

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS

Results of TRODELVY^® real-world data